✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

CORONA Remedies Ltd.

CORONA

Market Cap
₹11,920 Cr.
P/E
64.39

CORONA Remedies Ltd.

  • CORONA Remedies
  • Abbott India
  • Alkem Laboratories

FAQs on CORONA Remedies Ltd. Shareprice

There is not enough historical data for the companies share price.

Yes, CORONA Remedies is expensive.
Latest PE of CORONA Remedies is 64.39, while 3 year average PE is 61.3.
Also latest EV/EBITDA of CORONA Remedies is 43.25 while 3yr average is 35.72.

View FAQ's On Business

Growth Table

  • CORONA Remedies Ltd.
  • Abbott India
  • Alkem Laboratories

Balance Sheet

  • CORONA Remedies Ltd.
  • Abbott India
  • Alkem Laboratories

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • CORONA Remedies Ltd.
  • Abbott India
  • Alkem Laboratories

Cash Flow

  • CORONA Remedies Ltd.
  • Abbott India
  • Alkem Laboratories

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • CORONA Remedies Ltd.
  • Abbott India
  • Alkem Laboratories

Quarterly Results

  • CORONA Remedies Ltd.
  • Abbott India
  • Alkem Laboratories

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on CORONA Remedies Ltd. Financials

Balance sheet of CORONA Remedies is strong.
But short term working capital might become an issue for this company.

Yes, The net debt of CORONA Remedies is increasing.
Latest net debt of CORONA Remedies is ₹56.4 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹73.14 Crs.

Yes, profit is increasing.
The profit of CORONA Remedies is ₹185 Crs for Mar 2026, ₹149 Crs for Mar 2025 and ₹90.5 Crs for Mar 2024

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
CORONA Remedies latest dividend payout ratio is 33.04% and 3yr average dividend payout ratio is 29.32%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech